ORIC Pharmaceuticals has appointed Lori Friedman, PhD, Chief Scientific Officer. Dr. Friedman will serve on the executive leadership team and lead ORIC’s research and preclinical development efforts.   Dr. Friedman brings to ORIC over 20 years of experience in cancer research, including her 15-year career at Genentech, she was most recently head of translational oncology for Genentech Research and Early Development (gRED), where her team advanced more than 20 programs into clinical devel...